Dynamic Zero-Covid strategy curtails mutagenesis and emergence of new variants of the SARS-CoV-2
Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Yiyue Ge(Jiangsu Provincial Center for Disease Control and Prevention), Liguo Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Huafeng Fan(Jiangsu Provincial Center for Disease Control and Prevention), Guodong Kang(Dalian National Laboratory for Clean Energy), Yongxiang Yi(Nanjing University of Chinese Medicine), Changhua Yi(Nanjing University of Chinese Medicine), Guangjie Jin(Jiangsu Provincial Center for Disease Control and Prevention), Shenjiao Wang(Jiangsu Provincial Center for Disease Control and Prevention), Yudong Jiao(Northern Jiangsu People's Hospital), Yin Wang(Zhejiang Chinese Medical University), Jun Zhao(Northern Jiangsu People's Hospital), Jianli Hu(Union Hospital), Songning Ding(Jiangsu Provincial Center for Disease Control and Prevention), Xingsu Gao(Nanjing Medical University), Xu Han(University of Connecticut), Longyu Wang(Nanjing University of Chinese Medicine), Changjun Bao(Jiangsu Provincial Center for Disease Control and Prevention), Furu Wang(Jiangsu Provincial Center for Disease Control and Prevention), Ming Wu(Wuhan Pulmonary Hospital), Jianguang Fu(Jiangsu Provincial Center for Disease Control and Prevention), Jun Zhang(Xiamen University), Jianjun Li(National Research Council Canada), Huiyan Yu(Jiangsu Provincial Center for Disease Control and Prevention), Huan Fan(Jiangsu Provincial Center for Disease Control and Prevention), Zhifeng Li(Jiangsu Provincial Center for Disease Control and Prevention), Xian Qi(Peking University), Yuying Dong(Yangzhou University), Xiaojuan Zhu(Liaoning Normal University), Zhong Zhang(Jiangsu Provincial Center for Disease Control and Prevention), Jinfu Wang(Fujian Medical University), Jian Li(Jiangsu Provincial Center for Disease Control and Prevention), Hongde Liu(Southeast University), Jingxin Li(Beijing Tongren Hospital), Fēi Dèng(Hubei University of Medicine), Ya Shen(Jiangsu Provincial Center for Disease Control and Prevention), Kangchen Zhao(Jiangsu Provincial Center for Disease Control and Prevention), Yao Huang(Yangzhou University), Jing Ai(University of California, Los Angeles), Min He(Army Medical University)
Cited by 0
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Taxonomy of the order Bunyavirales: update 2019
|Archives of Virology|2019|398
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268